Health By Usha Lee McFarling National Academies report cites ‘urgent’ need to recruit more diverse participants for clinical trials
D.C. Diagnosis By Nicholas Florko As Congress takes up FDA oversight of dietary supplements, a lobbying showdown looms
Pharmalot By Ed Silverman Pharmalittle: FDA declines to approve old antidepressant for Covid; U.S.-China trade fight may derail WTO Covid patent waiver
First Opinion By Danielle Wenner and Gabriela Arguedas RamÃrez Omitting long Covid from pandemic messaging is harmful for public health
First Opinion By Joe Lieberman and Michelle McMurry-Heath Russian aggression underscores the U.S.’s need for greater investment in medical countermeasures
Hospitals By Tara Bannow Life or death decisions and no feedback: New study highlights the value of patient tracking, especially in the ER
Pharmalot By Ed Silverman Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Politics By David Nather and Dylan Scott FDA issues sweeping regulations for e-cigarettes for first time